Features of the ViewRay system, which is designed for the treatment of cancer, include continuous soft-tissue imaging and the combination of radiotherapy delivery and simultaneous magnetic resonance imaging.
“FDA clearance of our integrated system is a major milestone in the development of our technology,” said ViewRay President and CEO Gregory M. Ayers, MD, PhD, in the release. “It has already been an exciting year for ViewRay, with an additional round of funding and the installation of our first research systems at major U.S. medical centers. Early clinical imaging studies have verified the quality of the system’s MR images, and now we’re looking forward to clinical applications.”
ViewRay is headquartered in Oakwood Village, Ohio.
Related Articles on FDA Clearances:
ETView Medical Receives FDA 510(k) Clearance for Line of Innovative Airway Devices
Medspira Receives FDA 510(k) Clearance for Anorectal Manometry Device
MAQUET Cardiovascular Receives FDA 510(k) Clearance for New Intra-Aortic Balloon Catheter Sizes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.